When conoidin A was injected intraperitoneally to mice bearing HT29-derived tumor xenografts, conoidin A treatment significantly retarded the tumor growth compared to the control treatment (Fig. 6e and f); the result supports that PrxII inhibition can be a novel targeted therapy for human CRC. This evidence concerns the gene PRDX2 and colorectal carcinoma.